Bausch Health reported Q4 2025 consolidated revenues of USD 2.80 billion (+9%) and FY 2025 revenues of USD 10.27 billion (+7%). Q4 2025 net loss attributable to shareholders was USD 112 million, while FY 2025 net income attributable to shareholders was USD 157 million. Q4 2025 adjusted EBITDA attributable to shareholders was USD 1.05 billion (+13%) and FY 2025 adjusted EBITDA attributable to shareholders was USD 3.54 billion (+7%). Q4 2025 operating income was USD 474 million, reflecting a USD 145 million goodwill impairment charge related to the Generics business unit. By segment in Q4 2025, Salix revenue was USD 693 million (+9%), International USD 306 million (+10%), Solta Medical USD 137 million (down 1%), Diversified Products USD 255 million (+12%), and Bausch + Lomb USD 1.41 billion (+10%). For FY 2025, Salix revenue was USD 2.58 billion (+11%), International USD 1.13 billion (+2%), Solta Medical USD 518 million (+18%), Diversified Products USD 937 million (down 1%), and Bausch + Lomb USD 5.10 billion (+6%). The company generated USD 495 million of cash from operating activities in Q4 2025 and USD 1.40 billion in FY 2025. Business and corporate updates included completion of the acquisition of Shibo’s full-service aesthetics distribution business in China on Dec. 1, 2025; a USD 1.7 billion debt exchange offer in Q4 2025 and USD 9.6 billion of total refinancing in FY 2025; and R&D updates including initiation of a Phase 3 trial for larsucosterol in alcohol-associated hepatitis (first patient randomized in January 2026) and Australia approval for the Fraxel FTX system in December 2025. The company also said January 2026 topline Phase 3 results for RED-C did not achieve the primary endpoint. For FY 2026, Bausch Health issued revenue guidance of USD 10.63 billion to USD 10.88 billion and adjusted EBITDA guidance of USD 3.88 billion to USD 4.00 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602181605PR_NEWS_USPR_____NY90046) on February 18, 2026, and is solely responsible for the information contained therein.